Leadership Team

 

John Edwards, Executive ChairmanJohn Edwards

Executive Chairman
John Edwards has 30 years of biopharmaceutical leadership experience which includes drug discovery, product development, commercialization, and business development. He has been involved in the development of over 10 FDA approved biologics and building five consecutive successful biotechnology companies. Along with ImmuneXcite, John is also Executive Chair of F-star. Previously, John helped lead Adnexus from a start-up to the $450M acquisition by BMS within 4 years, where he then continued with the company for the next 3 years serving as President. Prior to joining Adnexus, John was Vice President of Sales, Marketing, and Medical Affairs at Transkaryotic Therapies. Additionally, during his 15-year tenure with Genetics Institute/Wyeth, John held senior-level positions in R&D, manufacturing, and commercial operations, during which time he was responsible for building what has become a >$1B global pharmaceutical business in hematology. Following the acquisition of Genetics Institute by Wyeth he held senior-level positions in U.S. and global marketing at Wyeth, where he successfully launched 4 products in 3 different therapeutic areas (hematology, oncology, and immunology). John started his career at Genzyme (pre-IPO), working in R&D. John received his M.B.A. from Boston University and his B.S. in Chemical Engineering from the University of Massachusetts, Amherst.

 

Eric FurfineEric Furfine
Chief Scientific Officer and Acting CEO
Eric S. Furfine, Ph.D. joined ImmuneXcite as Chief Scientific Officer and acting-Chief Executive Officer in February 2016. Prior to ImmuneXcite, Eric spent 5 years at Eleven Biotherapeutics, where his roles included Chief Scientific Officer and President of Research and Development. Previous to Eleven Biotherapeutics, he served as the Senior Vice President of Research and Preclinical Development of Adnexus Therapeutics, Inc., a Bristol-Myers Squibb research and development company, from August 2006 to December 2010. Additionally, Eric served as the Vice President of Preclinical Development of Regeneron Pharmaceuticals, Inc., and in various senior level research positions at GlaxoSmithKline plc. Eric received an A.B. from Washington University in St. Louis and a Ph.D. in Biochemistry from Brandeis University.

 

Chris PerleyChris Perley
Chief Development Officer
Chris Perley joined ImmuneXcite in August 2016 as Chief Development Officer. He has over 30 years of experience in the biopharmaceutical industry, supplying more than 30 biological products to the clinic and market. He has worked both in large pharma (Roche, Wyeth, and BMS) and in biotech (Genetics Institute, Dyax). Most recently Chris was Senior Vice President of Technical Operations at Dyax where he led the CMC team developing and supplying three development stage products and one commercial product. Chris worked for 20 years at the Wyeth/Genetics Institute Biotech Research, Development, and Manufacturing Center in Andover, MA where he built the clinical and commercial manufacturing infrastructure, eventually becoming the Managing Director and growing the site to over 2000 employees. During this time Chris was a member of the executive team that developed a global network of six plants supplying biotech products with revenue in excess of $10 billion. Chris received an S.B. in Chemical Engineering and S.M. in Biochemical Engineering from MIT, and an M.B.A. from Boston University’s Executive Program.

 

Ifat Rubin-Bejerano, Co-Founder and Head of ResearchIfat Rubin-Bejerano, Ph.D.
Co-Founder and Head of Research
Dr. Ifat Rubin-Bejerano is a Co-Founder of ImmuneXcite and serves as its Head of Research. She conducted her postdoctoral studies at the Whitehead Institute of MIT with Prof. Gerald R. Fink, where she was interested in the host-pathogen interaction of fungi with immune cells. Her research led to the identification of a fungal carbohydrate that recruits and activates neutrophils, which she then conjugated to cancer-specific antibodies to direct neutrophils to tumors. Ifat has been instrumental in translating the basic science into a commercial platform technology and has been leading the R&D efforts at ImmuneXcite. Dr. Rubin-Bejerano holds a Ph.D. and a B.Sc. magna cum laude from the Technion-Israel Institute of Technology.